Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
Aug. 22, 2019: Links between thiamine deficiency and cognitive issues; HIV in cerebrospinal fluid and neurocognitive impairment; frailty, depression, and symptomatic cognitive issues; alcohol consumption and HIV disease progression.
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.